Brian Park, PharmD

Drug Information Specialist https://www.clinicaladvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Ob/Gyn Information Center

Fezolinetant Reduces Vasomotor Symptoms Associated With Menopause

Brian Park, PharmD

March 3, 2021

Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.

Vaccine Information Center

Pfizer-BioNTech COVID-19 Vaccine: New Storage Conditions Approved; Booster Dose Study Initiated

Brian Park, PharmD

February 26, 2021

Previously, the labeling stated that the undiluted vials must be stored in an ultra-low temperature freezer.

Vaccine Information Center

Tick-Borne Encephalitis Vaccine Gets Priority Review

Brian Park, PharmD

February 26, 2021

TicoVac is an inactivated whole virus vaccine developed using a master ‘seed’ virus that is similar to the tick-borne encephalitis virus found in nature.

Investigational meningococcal vaccine may protect patients during outbreak

Pediatrics Information Center

ACIP: 2021 Child and Adolescent Immunization Schedule Updates

Brian Park, PharmD

February 19, 2021

Fewer childhood vaccines have been administered due to a decline in outpatient pediatric visits resulting from the COVID-19 pandemic.

Pediatrics Information Center

Nerivio Device Cleared for Migraine in Adolescents

Brian Park, PharmD

February 1, 2021

The approval was based on data from an open-label, single-arm study that evaluated the efficacy and safety of Nerivio in patients aged 12 to 17 years with migraine.

HIV/AIDS Information Center

Cabenuva Approved as First Long-Acting Injectable for HIV Treatment

Brian Park, PharmD

January 25, 2021

The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation.

Heart Failure Information Center

Empagliflozin Under Review for Heart Failure With Reduced Ejection Fraction

Brian Park, PharmD

January 18, 2021

The sNDA is supported by data from the phase 3 EMPEROR-Reduced trial which compared the efficacy and safety of empagliflozin to placebo, in addition to recommended therapy, in 3730 patients with chronic heart failure with reduced ejection fraction.

Gastroenterology Information Center

Clinical Remission Observed With Risankizumab in Crohn Disease Trials

Brian Park, PharmD

January 12, 2021

Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.

Oncology Information Center

Opdivo No Longer FDA-Approved for Small Cell Lung Cancer

Brian Park, PharmD

January 12, 2021

In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.

Vaccine Information Center

Vaccine Candidate AZD1222 Effective Against COVID-19

Brian Park, PharmD

November 23, 2020

A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.

Next post in Vaccine Information Center